Roche Expected To File Second Anti-Generic Suit In India
This article was originally published in PharmAsia News
Executive Summary
Roche is stepping up its legal fight against India's Cipla over the latter's attempts to market a generic of Valcyte (valganciclovir) for treating HIV/AIDS infections. Roche is expected to intensify the fight by filing in the Madras high court, adding to its legal efforts against Cipla. Another suit already has been filed in the Delhi high court, seeking an injunction against Cipla on grounds its generic infringes on the patent for Tarceva (erlotinib), Roche's anti-cancer drug. The Valcyte suit is expected to be filed in the Madras court because it was patented in the Chennai patent office. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.